Publication | Closed Access

Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study

Hematological MalignancyOncologyHematologyClinical TrialsMyeloid NeoplasiaIxazomib-based RegimensClinical Trial OutcomesMedicineRelapsed/refractory Multiple MyelomaEpidemiologyHealth Sciences